{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-037162","form_type":"8-K","ticker":"RBOT","cik":"0001812173","company_name":"Vicarious Surgical Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.275493+00:00","generated_at":"2026-06-03T05:41:58.614459+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vicarious Surgical reports Q1 2024 net loss of $17.0M; cash burn guidance unchanged at $50M","bullets":["GAAP net loss $17.0M ($0.10/sh) vs $26.9M ($0.21) YoY; adjusted net loss $15.1M ($0.09).","Operating expenses fell 28% to $16.1M from $22.3M; R&D $10.0M, G&A $5.0M, S&M $1.1M.","Cash & investments $84.1M; Q1 cash burn $14.1M; FY 2024 cash burn guidance reaffirmed at ~$50M.","Completed spring cadaver lab; refining V1.0 system ahead of final integration in fall 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-037162","json":"https://secwatch.observer/filing/0001213900-24-037162.json","markdown":"https://secwatch.observer/filing/0001213900-24-037162.md","text":"https://secwatch.observer/filing/0001213900-24-037162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024037162/0001213900-24-037162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024037162/ea0204772-8k_vicarious.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:41:58.614459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f9b52f39e2c76940f133365ed4eb9473f78cdd3","claim":"Vicarious Surgical Inc. reported the quarter ended March 31, 2024 results: net income GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10, EPS $0.10. Guidance reaffirmed.","evidence_excerpt":"Vicarious Surgical Reports First Quarter 2024 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024037162/0001213900-24-037162-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10"},{"label":"EPS","value":"$0.10"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}